| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Yusaku Yoshimura, Toshihiko Takeda, Yoshiki Kishi, Toshiki Harada, Akira Nomura, Kenji Washida, Bunta Yoshimura, Kojiro Sato, Yuji Yada, Shozo Aok. Two-year effectiveness of risperidone and aripiprazole in the maintenance treatment of patients with recent-onset or chronic schizophrenia and related psychotic disorders: a retrospective multicenter study. International clinical psychopharmacology. vol 33. issue 3. 2019-02-25. PMID:29406406. |
this study aimed to assess the comparative effectiveness of risperidone (ris) versus aripiprazole (arp) in patients with recent-onset or chronic schizophrenia during maintenance treatment and to examine the interaction between illness duration and the effectiveness of the treatment. |
2019-02-25 |
2023-08-13 |
Not clear |
| Lulu Zhang, Hongbo Zheng, Rengrong Wu, Furong Zhu, Thomas R Kosten, Xiang-Yang Zhang, Jingping Zha. Minocycline adjunctive treatment to risperidone for negative symptoms in schizophrenia: Association with pro-inflammatory cytokine levels. Progress in neuro-psychopharmacology & biological psychiatry. vol 85. 2019-01-17. PMID:29678772. |
minocycline adjunctive treatment to risperidone for negative symptoms in schizophrenia: association with pro-inflammatory cytokine levels. |
2019-01-17 |
2023-08-13 |
Not clear |
| Leslie Citrom. Long-acting injectable antipsychotics update: lengthening the dosing interval and expanding the diagnostic indications. Expert review of neurotherapeutics. vol 17. issue 10. 2019-01-03. PMID:28832262. |
approved indications have expanded beyond schizophrenia to also include bipolar maintenance (risperidone microspheres and aripiprazole monohydrate) and schizoaffective disorder (paliperidone palmitate monthly). |
2019-01-03 |
2023-08-13 |
Not clear |
| Shen Li, Ying Gao, Hao Lv, Miaomiao Zhang, Lili Wang, Rui Jiang, Chengai Xu, Xueshi Wang, Ming Gao, Yukun He, Jie Li, Wei-Dong L. T Psychoneuroendocrinology. vol 88. 2018-12-31. PMID:29175720. |
in this study, 264 han chinese inpatients diagnosed with schizophrenia or schizoaffective disorder initiated treatment with olanzapine (n=131) or risperidone (n=133) and were followed for 12weeks. |
2018-12-31 |
2023-08-13 |
Not clear |
| Lourdes Anta, Jordi Llaudó, Ignacio Ayani, Javier Martínez, Robert E Litman, Ibón Gutierr. A phase II study to evaluate the pharmacokinetics, safety, and tolerability of Risperidone ISM multiple intramuscular injections once every 4 weeks in patients with schizophrenia. International clinical psychopharmacology. vol 33. issue 2. 2018-12-19. PMID:29112001. |
a phase ii study to evaluate the pharmacokinetics, safety, and tolerability of risperidone ism multiple intramuscular injections once every 4 weeks in patients with schizophrenia. |
2018-12-19 |
2023-08-13 |
Not clear |
| Alireza Ghajar, Mohammad-Reza Khoaie-Ardakani, Zahara Shahmoradi, Amir-Reza Alavi, Mohsen Afarideh, Mohammad-Reza Shalbafan, Maryam Ghazizadeh-Hashemi, Shahin Akhondzade. L-carnosine as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double-blind, randomized placebo-controlled trial. Psychiatry research. vol 262. 2018-12-11. PMID:29427913. |
l-carnosine as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: a double-blind, randomized placebo-controlled trial. |
2018-12-11 |
2023-08-13 |
Not clear |
| Ming Teng Koh, Paige S Ahrens, Michela Gallaghe. A greater tendency for representation mediated learning in a ketamine mouse model of schizophrenia. Behavioral neuroscience. vol 132. issue 2. 2018-12-11. PMID:29672108. |
chronic treatment with the antipsychotic drug, risperidone, in ketamine-exposed mice attenuated mediated learning, a finding that may be related to its known efficacy in reducing the positive symptoms of schizophrenia. |
2018-12-11 |
2023-08-13 |
mouse |
| Rong-Qin Wu, Chong-Guang Lin, Wei Zhang, Xiao-Dong Lin, Xing-Shi Chen, Ce Chen, Li-Jun Zhang, Zi-Ye Huang, Guang-Dong Chen, Da-Li Xu, Zhi-Guang Lin, Ming-Dao Zhan. Effects of Risperidone and Paliperidone on Brain-Derived Neurotrophic Factor and N400 in First-Episode Schizophrenia. Chinese medical journal. vol 131. issue 19. 2018-12-11. PMID:30246715. |
effects of risperidone and paliperidone on brain-derived neurotrophic factor and n400 in first-episode schizophrenia. |
2018-12-11 |
2023-08-13 |
Not clear |
| Rong-Qin Wu, Chong-Guang Lin, Wei Zhang, Xiao-Dong Lin, Xing-Shi Chen, Ce Chen, Li-Jun Zhang, Zi-Ye Huang, Guang-Dong Chen, Da-Li Xu, Zhi-Guang Lin, Ming-Dao Zhan. Effects of Risperidone and Paliperidone on Brain-Derived Neurotrophic Factor and N400 in First-Episode Schizophrenia. Chinese medical journal. vol 131. issue 19. 2018-12-11. PMID:30246715. |
risperidone and paliperidone have been the mainstay treatment for schizophrenia and their potential role in neuroprotection could be associated with brain-derived neurotrophic factor (bdnf) and n400 (an event-related brain potential component). |
2018-12-11 |
2023-08-13 |
Not clear |
| Rong-Qin Wu, Chong-Guang Lin, Wei Zhang, Xiao-Dong Lin, Xing-Shi Chen, Ce Chen, Li-Jun Zhang, Zi-Ye Huang, Guang-Dong Chen, Da-Li Xu, Zhi-Guang Lin, Ming-Dao Zhan. Effects of Risperidone and Paliperidone on Brain-Derived Neurotrophic Factor and N400 in First-Episode Schizophrenia. Chinese medical journal. vol 131. issue 19. 2018-12-11. PMID:30246715. |
this study aimed to compare the effects of risperidone and paliperidone on bdnf and the n400 component of the event-related brain potential in patients with first-episode schizophrenia. |
2018-12-11 |
2023-08-13 |
Not clear |
| Marise W J Machielsen, Dick J Veltman, Wim van den Brink, Lieuwe de Haa. Comparing the effect of clozapine and risperidone on cue reactivity in male patients with schizophrenia and a cannabis use disorder: A randomized fMRI study. Schizophrenia research. vol 194. 2018-11-13. PMID:28351544. |
comparing the effect of clozapine and risperidone on cue reactivity in male patients with schizophrenia and a cannabis use disorder: a randomized fmri study. |
2018-11-13 |
2023-08-13 |
Not clear |
| Narjes Hendouei, Samaneh Farnia, Farhad Mohseni, Azadeh Salehi, Maedeh Bagheri, Faezeh Shadfar, Fatemeh Barzegar, Seyed Davood Hoseini, Jamshid Yazdani Charati, Fatemeh Shak. Alterations in oxidative stress markers and its correlation with clinical findings in schizophrenic patients consuming perphenazine, clozapine and risperidone. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. vol 103. 2018-11-13. PMID:29710513. |
therefore, in this study, we evaluated the level of oxidative stress parameters between patients treated with perphenazine, clozapine and risperidone and their relationship with schizophrenia symptoms' severity. |
2018-11-13 |
2023-08-13 |
Not clear |
| Ming Teng Koh, Yi Shao, Sharon Rosenzweig-Lipson, Michela Gallaghe. Treatment with levetiracetam improves cognition in a ketamine rat model of schizophrenia. Schizophrenia research. vol 193. 2018-11-09. PMID:28634087. |
levetiracetam remained effective when administered concurrently with risperidone, supporting potential viability of adjunctive therapy with levetiracetam to treat cognitive deficits in schizophrenia patients under concurrent antipsychotic therapy. |
2018-11-09 |
2023-08-13 |
rat |
| Maju Mathews, Huiling Pei, Adam Savitz, Isaac Nuamah, David Hough, Larry Alphs, Srihari Gopa. Paliperidone Palmitate 3-Monthly Versus 1-Monthly Injectable in Patients With Schizophrenia With or Without Prior Exposure to Oral Risperidone or Paliperidone: A Post Hoc, Subgroup Analysis. Clinical drug investigation. vol 38. issue 8. 2018-11-09. PMID:29882073. |
paliperidone palmitate 3-monthly versus 1-monthly injectable in patients with schizophrenia with or without prior exposure to oral risperidone or paliperidone: a post hoc, subgroup analysis. |
2018-11-09 |
2023-08-13 |
Not clear |
| Ying Chen, Yang Deng, Miao Yan, Zhenyan Hou, Yao Li, Bikui Zhang, Hualin Ca. Genotyping as a Key Element of Sample Size Optimization in Bioequivalence of Risperidone Tablets. European journal of drug metabolism and pharmacokinetics. vol 43. issue 4. 2018-10-23. PMID:29404931. |
risperidone is a derivative of benzisoxazole and is widely used for schizophrenia and other psychiatric illnesses in both adults and children. |
2018-10-23 |
2023-08-13 |
Not clear |
| Xiao-Jia Jiang, Fu-Xi Wu, Jian-Ping Zhang, Lei Shi, Jin-Qing Hu, Hai-Zhen Zhu, Bing Xiao, Wei-Cheng Lin, Yu-Guan Wen, De-Wei Shan. Effects of Risperidone and Aripiprazole on Serum Levels of Prolactin, Testosterone and Estradiol in Female Patients with Schizophrenia. Drug research. vol 68. issue 7. 2018-10-18. PMID:29482256. |
effects of risperidone and aripiprazole on serum levels of prolactin, testosterone and estradiol in female patients with schizophrenia. |
2018-10-18 |
2023-08-13 |
Not clear |
| Xiao-Jia Jiang, Fu-Xi Wu, Jian-Ping Zhang, Lei Shi, Jin-Qing Hu, Hai-Zhen Zhu, Bing Xiao, Wei-Cheng Lin, Yu-Guan Wen, De-Wei Shan. Effects of Risperidone and Aripiprazole on Serum Levels of Prolactin, Testosterone and Estradiol in Female Patients with Schizophrenia. Drug research. vol 68. issue 7. 2018-10-18. PMID:29482256. |
to evaluate the effects of treatment with risperidone and aripiprazole on serum prolactin, testosterone and estradiol levels in female patients with schizophrenia in china. |
2018-10-18 |
2023-08-13 |
Not clear |
| Li-Juan Gao, Hua-Gui Guo, Zhen-Tao Liang, Xiao-Xiao Zhong, Jin-Cai Zhu, Yu Yan. [Aripiprazole for drug-induced sexual dysfunction in schizophrenic males]. Zhonghua nan ke xue = National journal of andrology. vol 23. issue 7. 2018-10-12. PMID:29723454. |
to investigate the clinical effects of aripiprazole on sexual dysfunction induced by amisulpride or risperidone in male patients with schizophrenia. |
2018-10-12 |
2023-08-13 |
Not clear |
| Alain Bruno Tagne Nouemss. Risperidone-associated sinus tachycardia potentiated by paliperidone palmitate in a patient with no prior cardiovascular disease: role of risperidone-related autonomic instability. BMJ case reports. vol 2018. 2018-10-11. PMID:29680794. |
risperidone and paliperidone palmitate are two antipsychotic drugs well tolerated in the management of schizophrenia and other psychiatric conditions. |
2018-10-11 |
2023-08-13 |
Not clear |
| Lei Zeng, ChuanYuan Kang, Jing Yuan, Yan Zhang, YuJun Wei, Li Xu, Fang Zhou, JianZhong Yan. CYP2D6 polymorphisms are associated with effects of risperidone on neurocognitive performance in schizophrenia. Schizophrenia research. vol 188. 2018-10-02. PMID:28131599. |
cyp2d6 polymorphisms are associated with effects of risperidone on neurocognitive performance in schizophrenia. |
2018-10-02 |
2023-08-13 |
Not clear |